Author

J.-P. Brosseau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

J. Xu· 2 shared C. Fang· 1 shared C. Li· 1 shared H. Lu· 1 shared H. Shi· 1 shared H. Wang· 1 shared H. Yao· 1 shared J. Lan· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

J. Xu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintFeb 25, 2022

The ITPRIPL1- CD3ϵ axis: a novel immune checkpoint controlling T cells activation

S. Deng, Y. Wang, J.-P. Brosseau…·J. Xu

The paper identifies ITPRIPL1 as a novel immune checkpoint that inhibits T cell activation by interacting with CD3ε, suggesting it as a therapeutic target for PD-1/PD-L1 negative tumors.

DOI 10.1101/2022.02.25.481189

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 2, 2019

Palmitoylation is critically required for cancer intrinsic PD-1 expression and functions

H. Yao, C. Li, J.-P. Brosseau…·J. Xu

This study identifies PD-1 palmitoylation, its regulatory enzyme, and develops a peptide inhibitor to target PD-1 expression for cancer immunotherapy.

DOI 10.1101/625483

humanproteomics

𝕏 PostBluesky